Formula (Cancidas 01)
Cancidas Injection, Powder, Lyophilized, For Solution
Product Images NDC 0006-3822
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Cancidas (NDC 0006-3822). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Chemical Structure (Cancidas 02)
Principal Display Panel (50 mg Vial Carton)
Principal Display Panel (70 mg Vial Carton)
This is a medication called caspofungin, which is for intravenous use only. The dosage and storage instructions are given, along with the preparation instructions, which involve adding sodium chloride solution to caspofungin and diluting it further before infusion. The solution must be used within a certain time frame depending on the storage temperature, and it should not be used with diluents that contain dextrose. The medication is available in a vial containing 70 mg of caspofungin that must be reconstituted with 108 mL of diluent to obtain a concentration of 7 mg/mL. There is additional information about the inactive ingredients present, such as sucrose, mannitol, and acetic acid.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
